Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

83.18EUR
23 May 2018
Change (% chg)

€-1.30 (-1.54%)
Prev Close
€84.48
Open
€84.14
Day's High
€84.32
Day's Low
€82.50
Volume
636,342
Avg. Vol
635,364
52-wk High
€112.65
52-wk Low
€74.54

Latest Key Developments (Source: Significant Developments)

Merck KGaA Receives Patent For CRISPR Technology In China
Monday, 23 Apr 2018 

April 23 (Reuters) - Merck KGaA ::MERCK RECEIVES PATENT FOR CRISPR TECHNOLOGY IN CHINA.  Full Article

P&G Acquires the Consumer Health Business Of Merck KGaA, Darmstadt, Germany
Thursday, 19 Apr 2018 

April 19 (Reuters) - Procter & Gamble Co ::ACQUIRES THE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.SAYS ANNOUNCED IT HAS SIGNED AN AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.HAS SIGNED AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, FOR PURCHASE PRICE OF ABOUT 3.4 BILLION EURO.  Full Article

P&G Nears Deal To Acquire Merck KGaA's Consumer-Health Unit - WSJ
Thursday, 19 Apr 2018 

April 18 (Reuters) - :P&G NEARS DEAL TO ACQUIRE MERCK KGAA’S CONSUMER-HEALTH UNIT - WSJ, CITING SOURCES.  Full Article

Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Merck KGAA ::FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER.  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

HTG Molecular Diagnostics Expands Its Collaboration With Merck
Wednesday, 27 Dec 2017 

Dec 26 (Reuters) - Htg Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS EXPANDS ITS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY.HTG MOLECULAR - TO DEVELOP CUSTOM PROFILING ASSAY TO SUPPORT BIOMARKER RESEARCH FOR 6 INDICATIONS WITHIN MERCK KGAA'S DRUG DEVELOPMENT PIPELINE.  Full Article

Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY.  Full Article

FDA grants second breakthrough therapy designation for Avelumab in hard-to-treat cancer​
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Merck Kgaa ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.SAYS ‍SECOND BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN HARD-TO-TREAT CANCER​.SAYS ‍RENAL CELL CARCINOMA, MOST COMMON FORM OF KIDNEY CANCER, HAS A POOR PROGNOSIS IN ADVANCED STAGE​.SAYS ‍JAVELIN RENAL CLINICAL DEVELOPMENT PROGRAM IS ONGOING, INCLUDING PHASE III FIRST-LINE STUDY​.SAYS ‍FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA(®) (AXITINIB)* FOR TREATMENT-NAÏVE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA​.  Full Article

Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - MERCK KGAA ::MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS.  Full Article

Photo

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find a drug-industry partner to share further development costs for one of them.